REG - Craven House Capital - Investee company update: RoseMonkey Ltd

Craven House CapitalAnnouncement

10/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240910:nRSJ5075Da&default-theme=true

RNS Number : 5075D  Craven House Capital PLC  10 September 2024

Craven House Capital PLC

10 September 2024

Certain information contained within this Announcement is deemed by the
Company to constitute inside information as stipulated under the Market Abuse
Regulation (EU) No. 596/2014 ("MAR") as applied in the United Kingdom. Upon
publication of this Announcement, this information is now considered to be in
the public domain.

 

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: RoseMonkey Ltd

The Company confirms that RoseMonkey Ltd (a company in which Craven has a
24.4% shareholding in) has notified it that it has sold certain IP rights and
participated in a financing transaction with Quiapeg Pharma AB ("QuiaPeg").

Following completion of the transactions, RoseMonkey was awarded 1,416,007,811
shares in QuiaPeg. RoseMonkey elected to distribute a proportionate amount of
those shares to Craven House.

Craven House has therefore received 345,505,096 shares representing 23.2% of
QuiaPeg and a market value of approximately $758,792 as at September 9(th),
2024.

QuiaPeg is a drug development company based on a patented drug delivery
platform, Uni-Qleaver®, and the company develops improved and patentable
forms of drugs under development or already approved by regulatory
authorities. QuiaPEG's shares are admitted to trading on Nasdaq First North
Growth Market.

Craven House remains a 24.4% shareholder in RoseMonkey Ltd.

For further information please contact:

 Craven House Capital Plc                                                Tel: 0203 286 8130

 Mark Pajak

 www.Cravenhousecapital.com (http://www.cravenhousecapital.com/)

 SI Capital                                                              Tel: 01483 413500

 Broker

 Nick Emerson

 www.sicapital.co.uk (http://www.sicapital.co.uk/)

 SPARK Advisory Partners Limited                                         Tel: 0203 368 3550

 Nominated Adviser

 Matt Davis

 www.Sparkadvisorypartners.com (http://www.sparkadvisorypartners.com/)

 

 About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a
portfolio of companies, partnerships, joint ventures, businesses or other
assets participating in the e-Commerce sector.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAFNNEASLEAA